Tier 4 — mechanistic
Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate lipopolysaccharide-induced microglial and astrocytic neuroinflammation by increasing NAD+
Journal of Neurochemistry
2021
158(2):311-327
Bibliography
- PubMed
- PMID 33871064
- PubMed Central
- PMC8282715
- Funding
- Indexed grant support includes NCI NIH HHS. The complete funding declaration is not specified in the accessible abstract.
- Competing interests
- A complete competing-interest declaration is not specified in the accessible publication information.
Study snapshot
| Design | In vivo mouse and primary-cell mechanistic study |
|---|---|
| Model | LPS-induced neuroinflammation in mice and primary microglia/astrocytes |
| Sample | LPS-challenged mice and primary glial cultures |
| Intervention | Apigenin as a CD38 inhibitor and nicotinamide riboside as an NAD+ precursor |
| Duration | Pretreatment and inflammatory challenge protocols |
| Endpoints | NAD+ levels; Microglial and astrocytic activation; Inflammatory cytokines; CD38-related signaling |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
